Previous studies have demonstrated the potential role of PXR in prostate cancer cell sensitivity to taxane-based chemotherapies [27], but its role in the sensitivity to targeted therapies was not investigated though many kinase inhibitors have been tested in that indication. The gene discussed is NR1I2; the disease is Familial prostate cancer.